Alexion Pharmaceuticals (NASDAQ:ALXN) is expected to report second quarter results for 2012 before the market opens on Wednesday, July 25th followed by a conference call and audio web cast at 10 am ET. The company's profit for Q2 is expected to rise by 28% to.37 per share while analysts see revenue increasing 42% to $262M.
In recent months the stock has received several upgrades. The most recent, The Street reiterating a Buy due to the company's strong revenue growth, prominent return on equity, solid record of earnings per share growth and healthy growth in net income.
The Street's rating report shows that Alexion's revenue growth has surpassed the industry average of 3.9%. Revenue has risen 47% year over year, as well as, EPS growing to$ .91 vs $.53 the prior year. The company has demonstrated a pattern of positive EPS growth and it looks as if that trend will continue.
To join Alexion's call:
Conference call: 866-804-6925, passcode 13237521
Replay: 888-286-8010, passcode 42568134
Audio webcast: www.alexionpharma.com
Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in ALXN over the next 72 hours.